Matthias Tschöp, M.D., discovered major principles of gut-brain communication and translated these into novel therapeutics for diabetes and obesity. He received his M.D. from the University of Munich where he trained as a resident before joining the Eli Lilly Research Laboratories in Indianapolis, USA. There he discovered the orexigenic, adipogenic and metabolic effects of ghrelin as well as its regulation by nutrients and body weight, establishing one of today’s fundamental metabolic pathways. He then returned to academia and served as the Arthur Russell Morgan Endowed Chair of Medicine at the Diabetes Center of Excellence, University of Cincinnati. He and his long-term collaborator Dr. Richard DiMarchi discovered several new classes of unimolecular gut hormone-based combinatorial therapeutics, many of which are now in clinical development for the treatment of diabetes and obesity.
Dr. Tschöp has received numerous awards and honours including the ADA & TOS Outstanding Scientific Achievement Awards, the NIH/NIDDK Scholar Award, the Erwin Schrödinger Prize and the Bayer Foundations Hansen Family Award. He is an elected member of the German National Academy of Science (Leopoldina) and has received an honorary doctorate from the University of Leipzig.
Dr. Tschöp currently serves as Alexander von Humboldt Professor and Chair of Metabolic Diseases at Technical University of Munich and directs the Helmholtz Diabetes Center and Pioneer Campus at Helmholtz Zentrum München.
« Go Back